(KRS 0000751680, NIP ) is a Polish company. operates in: Research and experimental development on biotechnology (PKD 72.11.Z). Industry: Research and development. The company has been listed in the National Court Register since October 5, 2018. 's most recently reported net revenue was 0 PLN for 2024.
Negative equity
Negative equity in 1 of 3 available reporting years.
No arrears identified in the analysed sources
No arrears or bankruptcy proceedings identified in the analysed sources.
Business profile
Identity
- Name
- Legal form
- Founded
- October 5, 2018
- Registry status as of
- June 26, 2026
- Latest entry
- June 26, 2026
Activities
Other activities
Address and contact
- Address
- Voivodeship
- District
- Not disclosed in the registry
- Website
- Not disclosed in the registry
- E-delivery address
- Not disclosed in the registry
Risk and payment profile
Credibility rating
24.1 / 100
Poor credibility
Insolvency risk
Low
Elevated threat
Closure risk
39
/ 100
Risk comparison - scale 0 (safe) → 100 (critical)
Organisational stability signals
No instability signals - ownership, management, PKD codes and company name remain relatively stable.
Shareholder changes
0
0/8 yrs
Board changes
1
1/8 yrs
PKD changes
0
0/8 yrs
Name changes
0
0/8 yrs
Data from 8 years of registry activity.
Credibility history
Payment reliability score from 2018–2024
Current: E (24/100)
Trend: deteriorating (-10.9 pts/year)
Bardzo słaba wiarygodność płatnicza – współpraca handlowa wiąże się z wysokim ryzykiem braku zapłaty.
Trade credit limit history
Standard limit from 2018–2024
Current: 0 PLN
Safe: 0 PLN
Difference between risk models
Closure - probability of ceasing operations (operational continuity). Insolvency - probability of formal bankruptcy / restructuring. The models use different data - results can diverge significantly when balance-sheet data is incomplete.
Operational status
Founded
October 5, 2018
7 years in operation
Legal form
N/A
Registry: RejP
Headquarters
N/A
Primary PKD
72.11.Z
Research and experimental development on biotechnology
Share capital
N/A
Shareholders
N/A
Board
2 people
Filed years
3 years
2018–2024 · profitable: 0/3
Registry entries
14
latest: June 26, 2026
Risk signals
Revenue
0 PLN
2024
Net profit
-265.9 K PLN
2024
Assets
26.9 K PLN
2024
Equity
-2.6 K PLN
2024
Valuation
13.0 K PLN
Low confidence
Low confidence
Public procurement
Trademarks
Reviews
Rate business credibility - .
No ratings
Related articles
News
Bioceltix in the final EMA dialogue phase: BCX-CM-J could become Europe's first veterinary cell-therapy drug for dogs
Wrocław-based Bioceltix S.A. (KRS 0000744521) entered Q2 2026 in the final EMA dialogue phase on BCX-CM-J – potentially Europe's first veterinary cell-therapy drug based on mesenchymal stem cells, for dogs with osteoarthritis. Responses to the EMA's final questions are due in May 2026; a CVMP recommendation and marketing authorisation are possible in Q3/Q4 2026. A pre-commercial biotech: it closed 2024 with a PLN 14.9m loss on zero revenue and PLN 33.6m of cash at year-end. Trigon DM maintains a buy rating with a PLN 127.2 price target.
News
Captor Therapeutics: PLN 36m of cash at 30 September 2025, runway to mid-2026 – clinical data versus the cash clock
Wrocław-based Captor Therapeutics S.A. (KRS 0000756383) – a pre-commercial biotech specialising in targeted protein degradation (TPD) – closed Q3 2025 with PLN 36m of cash and grants securing funding to mid-2026. CT-01 (hepatocellular carcinoma) entered Phase I, with the first patient dosed at the Barcelona Clinic Liver Cancer. CT-03, an MCL-1 degrader, is close to clinical entry. Without a new R&D partnership or share issue in 2026, the company will need additional financing.
